0 avis
Left Ventricular Abnormal Substrate in Brugada Syndrome
Archive ouverte
International audience. BackgroundSlow-conductive structural abnormalities located in the epicardium of the right ventricle (RV) underlie Brugada syndrome (BrS). The extent of such substrate in the left ventricle (LV) has not been investigated.Objectives This study sought to characterize the extent of epicardial substrate abnormalities in BrS.Methods We evaluated 22 consecutive patients (mean age 46 +/- 11 years, 21 male) referred for recurrent ventricular arrhythmias (mean 10 +/- 13 episodes) in the setting of BrS. The patients underwent clinical investigations and wide genetic screening to identify SCN5A mutations and common risk variants. High-density biventricular epicardial mapping was performed to detect prolonged (>70 ms) fragmented electrograms, indicating abnormal substrate area.Results All patients presented with abnormal substrate in the epicardial anterior RV (27 +/- 11 cm(2)). Abnormal substrate was also identified on the LV epicardium in 10 patients (45%), 9 at baseline and 1 after ajmaline infusion, covering 15 +/- 11 cm(2). Of these, 4 had severe LV fascicular blocks. Patients with LV substrate had a longer history of arrhythmia (11.4 +/- 6.7 years vs 4.3 +/- 4.3 years; P = 0.003), longer PR (217 +/- 24 ms vs 171 +/- 14 ms; P < 0.001) and HV (60 +/- 12 ms vs 46 +/- 5 ms; P = 0.005) intervals, and abnormal substrate also extending into the inferior RV (100% vs 33%; P = 0.001). SCN5A mutation was present in 70% of patients with LV substrate (vs 25%; P = 0.035). SCN5A BrS patients with recurrent ventricular arrhythmias present a higher polygenic risk score compared with a nonselected BrS population (median of differences: -0.86; 95% CI: -1.48 to -0.27; P = 0.02).Conclusions A subset of patients with BrS present an abnormal substrate extending onto the LV epicardium and inferior RV that is associated with SCN5A mutations and multigenic variants.
Consulter en ligne
Suggestions
Du même auteur
